Brief: Pre-Clinical Data Of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects In Diabetic Retinopathy And Uveitis Published In The International Journal Of Molecular Sciences
18/04/2023 12:37
April 18 (Reuters) - Palatin Technologies Inc PTN.A :
* PRE-CLINICAL DATA OF PALATIN'S MELANOCORTIN AGONIST
DEMONSTRATING THERAPEUTIC EFFECTS IN DIABETIC RETINOPATHY AND
UVEITIS PUBLISHED IN THE INTERNATIONAL JOURNAL OF MOLECULAR
SCIENCES
Source text for Eikon: ID:nPn71B0Hwa
Further company coverage: PTN.A
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity